Boston Scientific Sees Grim Q2 But Eyes Growth By Q4 Fueled By Product Launches
The big news at Boston Scientific's first-quarter earnings call was how badly the pandemic had impacted the second quarter so far, with sales down almost $500m in April. But the company said it already saw signs that procedure volumes were beginning to bounce back.
You may also be interested in...
Pulsed field ablation, which uses a controlled electrical field instead of focused heat or cold, has shown promise as a safer alternative to thermal and cryo approaches for atrial fibrillation ablation.
The company’s sales declined 29% in the second quarter of 2020 due to the pandemic, but sales trends indicate the start of a worldwide recovery across all of Boston Scientific’s businesses.
Angelo De Rosa, VP of Boston Scientific's cardiac rhythm management business in Europe, the Middle East and Africa, talked to Medtech Insight about the opportunities to accelerate digital transformation in health care during the COVID-19 crisis.